ISAB logo

Inhalation Sciences Sweden AB (publ) Stock Price

NGM:ISAB Community·SEK 65.8m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

ISAB Share Price Performance

SEK 0
0.00 (0.00%)
SEK 0
0.00 (0.00%)
Price SEK 0

ISAB Community Narratives

There are no narratives available yet.

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet and fair value.

5 Risks
2 Rewards

Inhalation Sciences Sweden AB (publ) Key Details

SEK 17.5m

Revenue

SEK 3.5m

Cost of Revenue

SEK 14.0m

Gross Profit

SEK 18.7m

Other Expenses

-SEK 4.7m

Earnings

Last Reported Earnings
Dec 31, 2023
Next Reporting Earnings
May 28, 2024
-0.31
79.77%
-27.10%
8.4%
View Full Analysis

About ISAB

Founded
2004
Employees
8
CEO
Manoush Masarrat
WebsiteView website
www.inhalation.se

Inhalation Sciences Sweden AB (publ) develops and sells labtech equipment for inhalation research. The company’s products portfolio includes PreciseInhale, a laboratory system that allows scientists to measure how inhaled particles act in lungs and affect the health; DissolvIt, which enables in vitro simulation of dissolution and absorption of respirable particles in the lung epithelium; XposeALI, a 3D cell exposure module that combines aerosol capability with 3D cell models cultured at an air liquid interface; Nose-only inhalation, a standard method of exposure used in preclinical testing of inhalation drugs, as well as for inhalation toxicity studies in rodents; and intratracheal exposure module, an unique technology delivering aerosol directly to the lungs, bypassing the nose, and to spontaneously breathing rodents. Inhalation Sciences Sweden AB (publ) was founded in 2004 and is headquartered in Huddinge, Sweden.

Recent ISAB News & Updates

Recent updates

No updates